Skip to content

Using disposable bronchoscopy in the second generation of metagenomic sequencing technology to guide the early diagnosis of severe community-acquired pneumonia pathogens and the determination of anti-infective efficacy of clinical research

Using disposable bronchoscopy in the second generation of metagenomic sequencing technology to guide the early diagnosis of severe community-acquired pneumonia pathogens and the determination of anti-infective efficacy of clinical research

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063716
Enrollment
Unknown
Registered
2022-09-15
Start date
2022-09-15
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Interventions

Experimental group:disposable bronchoscopy
Control group:Conventional bronchoscopy

Sponsors

Xinqiao Hospital of Third Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years old, clearly diagnosed with community-acquired pneumonia, and in line with the Chinese adult community-acquired pneumonia diagnosis and treatment guidelines (2016 edition) SCAP diagnostic criteria; 2. Endotracheal intubation is less than 24 hours; 3. Willing to send alveolar lavage fluid for mNGS testing at their own expense for the first time.

Exclusion criteria

Exclusion criteria: 1. Bronchiectasis; 2. Patients with active pulmonary tuberculosis; 3. Obstructive pneumonia; 4. There is a history of hospitalization 2 weeks before the onset of illness, and this infection cannot be excluded for hospital-acquired infections; 5. Patients who have been hospitalized or received mechanical ventilation for >= 2 days before enrollment; 6. Immunosuppressed hosts: including HIV-positive patients, agranulocytosis lasting more than 10 days, bone marrow stem cell transplantation, solid organ transplantation, recent glucocorticoid pulse therapy, immunosuppressant therapy, patients with solid tumors receiving radiotherapy and chemotherapy, etc.; 7. Patients who cannot understand and implement the investigation plan; 8. Bronchoscopy and lavage examination cannot be performed.

Design outcomes

Primary

MeasureTime frame
Pathogenic microbial species;

Countries

China

Contacts

Public ContactFan Ye

Xinqiao Hospital of Third Military Medical University

83728087@qq.com+86 13983815728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026